{'fraction_non_alphanumeric': 0.05593220338983051, 'fraction_numerical': 0.006779661016949152, 'mean_word_length': 5.793103448275862, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Ranibizumab for age‐related macular degeneration: a meta‐analysis of dose effects and comparison with no anti‐VEGF treatment and bevacizumab

Ranibizumab is used monthly or as‐needed (PRN) for the treatment of age‐related macular degeneration. However, which treatment regimen is more effective remains unknown. The objectives of this study are to: (i) compare the efficacy of monthly versus as‐needed quarterly treatment; and (ii) compare the efficacy of ranibizumab 0·5 mg treatment with: (a) no anti‐vascular endothelial growth factor (VEGF); (b) ranibizumab 0·3 mg; and (c) bevacizumab.